Clinuvel Pharmaceuticals Ltd has released a press release.
CLINUVEL advances new formulations in preclinical program
Filed with ASX ·
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call6ix hasn’t read this filing yet.
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL to advance novel pharmaceutical formulations in preclinical program
- EMA approves year-round SCENESSE treatment
- SCENESSE efficacy in vitiligo - new cases presented to EADV
- Investor Presentation
- CLINUVEL delivers ninth consecutive revenues growth & profit
Later from Clinuvel Pharmaceuticals
- CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
- CLINUVEL expands Singapore RD&I Centre
- CLINUVEL - injectable peptide platform in preclinical study
- Appendix 4D and Half Year Report
- CLINUVEL Record Revenues, Advances Strategic Expansion
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals